Brainstorm Cell Therapeutics News

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Strukturierte Produkte

Aktion

Portfolio

Watchlist

30.12.23	BCLI FINAL DEADLINE TUESDAY: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Brainstorm Cell Therapeutics Inc. Investors with Losses in Excess of $500K to Secure Counsel Before Important January 2 Dead... (PR Newswire)
23.12.23	ROSEN, A TOP RANKED LAW FIRM, Encourages Brainstorm Cell Therapeutics Inc. Investors with Losses to Secure Counsel Before Important January 2 Deadline in Securities Class Action First Filed by the... (PR Newswire)
14.12.23	ROSEN, LEADING INVESTOR COUNSEL, Encourages Brainstorm Cell Therapeutics Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - BCLI (PR Newswire)
08.12.23	ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Brainstorm Cell Therapeutics Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - BCLI (PR Newswire)
07.12.23	BrainStorm Cell Says FDA Meeting Provides Clear Path For Planned Phase 3b Trial Of NurOwn In ALS (RTTNews)
28.11.23	SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Brainstorm Cell Therapeutics Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 2, 2024 - (NASDAQ: BCLI) (PR Newswire)
28.11.23	ROSEN, SKILLED INVESTOR COUNSEL, Encourages Brainstorm Cell Therapeutics Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - BCLI (PR Newswire)
27.11.23	SHAREHOLDER ALERT: The Law Offices of Vincent Wong Remind Brainstorm Cell Investors of a Lead Plaintiff Deadline of January 2, 2024 (PR Newswire)
21.11.23	SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Brainstorm Cell Therapeutics Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 2, 2024 - (NASDAQ: BCLI) (PR Newswire)
20.11.23	BrainStorm Cell Therapeutics: FDA Grants In-person Meeting To Discuss Best Path Forward For NurOwn (RTTNews)
20.11.23	SHAREHOLDER ALERT: The Law Offices of Vincent Wong Remind Brainstorm Cell Investors of a Lead Plaintiff Deadline of January 2, 2024 (PR Newswire)
16.11.23	ROSEN, A LEADING LAW FIRM, Encourages Brainstorm Cell Therapeutics Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - BCLI (PR Newswire)
16.11.23	SHAREHOLDER ALERT: Levi & Korsinsky Notifies Brainstorm Cell Therapeutics Inc.(BCLI) Investors of a Class Action Lawsuit and Upcoming Deadline (PR Newswire)
14.11.23	SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Brainstorm Cell Therapeutics Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 2, 2024 - (NASDAQ: BCLI) (PR Newswire)
09.11.23	ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Brainstorm Cell Therapeutics Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - BCLI (PR Newswire)
03.11.23	NATIONALLY RANKED ROSEN LAW FIRM Encourages Brainstorm Cell Therapeutics Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - BCLI (PR Newswire)
07.10.23	ROSEN, A TOP RANKED LAW FIRM, Encourages Brainstorm Cell Therapeutics Inc. Investors to Inquire About Securities Class Action Investigation - BCLI (PR Newswire)
30.09.23	BCLI LOSS ALERT: ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Brainstorm Cell Therapeutics Inc. Investors to Inquire About Securities Class Action Investigation - BCLI (PR Newswire)
28.09.23	BrainStorm: FDA Committee Votes NurOwn Failed To Show Substantial Evidence Of Effectiveness In ALS (RTTNews)
31.08.23	Biotech Stocks Facing FDA Decision In September 2023 (RTTNews)
07.08.23	BrainStorm to Announce Second Quarter 2023 Financial Results and Provide a Corporate Update (PR Newswire)
27.03.23	BrainStorm: FDA To Hold Advisory Committee Meeting To Discuss BLA For NurOwn (RTTNews)
04.01.23	BrainStorm Cell Therapeutics Promotes Stacy Lindborg To Work Alongside Chaim Lebovits As Co-CEO (RTTNews)
27.12.22	BrainStorm Says Type A Meeting With FDA Granted For NurOwn (RTTNews)
12.12.22	BrainStorm Submits Type A Meeting Request With FDA To Discuss Refusal To File Letter (RTTNews)
10.11.22	BrainStorm: FDA Refuses To File Letter Regarding BLA For NurOwn In ALS (RTTNews)
27.12.21	BrainStorm Announces Plans For Dosing Extension Of NurOwn - Quick Facts (RTTNews)
14.12.21	Pre-market Movers: XCUR, MIND, NES, APTO, ALZN… (RTTNews)
29.11.21	BrainStorm: Analyses Show Effect Of NurOwn On ALS Disease Progression In Less Severe Disease (RTTNews)
05.08.21	BrainStorm Announces Second Quarter 2021 Financial Results and Provides a Corporate Update (PR Newswire)
27.07.21	BrainStorm Increases Commercial Manufacturing Capacity; Granted GMP Certification for a Second Production Site in Israel (PR Newswire)
26.07.21	BrainStorm to Announce Second Quarter Financial Results and Provide a Corporate Update (PR Newswire)
15.06.21	Brainstorm Announces Expansion of NurOwn® IP Portfolio with Grant and Allowance of Multiple Patents and Applications in Major Markets (PR Newswire)
24.03.21	BrainStorm Announces Positive Data On Cell Therapy NurOwn As Treatment For Progressive MS; Stock Up (RTTNews)
23.02.21	BCLI Slips On FDA Feedback, OTIC Plunges As Ménière's Disease Trial Fails, CLNN On Watch (RTTNews)
18.11.20	BCLI Flunks Phase II ALS Study, LXRX Aces Sotagliflozin Trials, KZIA On Watch, FDA Snubs ALKS (RTTNews)
17.11.20	BrainStorm: Phase 3 Trial With NurOwn Fails To Meet Statistical Significance In Efficacy Endpoint (RTTNews)
23.10.20	Catalent und BrainStorm Cell Therapeutics geben Partnerschaft zur Herstellung von NurOwn®, einer auf mesenchymalen Stammzellen beruhenden Therapie, bekannt (GlobeNewswire)
22.10.20	Catalent and BrainStorm Cell Therapeutics Announce Partnership for the Manufacture of Mesenchymal Stem Cell Platform Therapy NurOwn® (GlobeNewswire)
06.08.20	ABIO To Start Phase 2 COVID-19 Trial In Q4, ACIU On Track, BCLI Expects ALS Trial Data In Nov. (RTTNews)
03.06.20	AGEN, AGE To Battle Coronavirus, BCLI Awaits ALS Trial Data, FDA Delays Decision On NVS' Drug (RTTNews)
07.05.20	Ausblick: Brainstorm Cell Therapeutics gibt Ergebnis zum abgelaufenen Quartal bekannt (finanzen.net)
26.12.18	BrainStorm Expands Manufacturing Of NurOwn For Phase 2 Progressive MS Trial (RTTNews)
03.07.18	FDA Nod For ALKS, TRXC Sees 4-fold Increase In Q2 Revenue, BCLI On Watch (RTTNews)
07.06.18	BrainStorm Announces Exercise of Warrants Resulting in Cash Proceeds of ~$12.3 Million at $5 Share (PR Newswire)
01.06.18	BrainStorm to Host Call Following President Trump's Citing of Company's ALS Treatment During "Right-to-Try" Bill Signing (PR Newswire)
30.05.18	BrainStorm Cell Therapeutics to Provide Corporate Update at the BIO International Convention (PR Newswire)
25.05.18	BrainStorm Cell Therapeutics Issues Statement on "Right to Try" Legislation (PR Newswire)
14.05.18	BrainStorm Announces First Quarter 2018 Financial Results and Provides Corporate and Clinical Highlights (PR Newswire)
09.05.18	BrainStorm CEO to Present at World Advanced Therapy and Regenerative Medicine Congress in London (PR Newswire)

Newssuche

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Logitech Intl	74.30	1.53 %	K V
Holcim	87.38	1.49 %	K V
Roche Hldg G	251.00	1.46 %	K V
Swiss Re	130.35	1.44 %	K V
UBS Group	27.07	1.35 %	K V
Swisscom	501.00	0.52 %	K V
Lonza Grp	532.40	0.26 %	K V
Nestle	74.08	0.14 %	K V
Sonova Hldg	295.60	0.00 %	K V
Geberit	512.20	-0.39 %	K V